510(k) device
Gem
Collins Medical, Inc. · Spirometer, Diagnostic (BZG, Class II) · First FDA decision Mar 14, 2003, newest May 14, 2003AsthmaCOPD and emphysema
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
15
Naming "Gem"
MAUDE reports
877
Brand "Gem", since 2015
PubMed studies
8,501
Mentioning "Gem"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Gem
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K030917 · Decided May 14, 2003 · 51 days after receipt
Device type: Spirometer, Diagnostic (BZG) · Anesthesiology & Respiratory
- GEM, MODEL 004110510(k)
K030464 · Decided Mar 14, 2003 · 30 days after receipt
Device type: Spirometer, Diagnostic (BZG) · Anesthesiology & Respiratory
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087NUpdated Sep 15, 2026
- Diabetes Outpatient Self-Management TrainingNational determinationOn the books40.1Updated Nov 27, 2024
- Facet Joint Interventions for Pain ManagementLocal determinationTakes effect soonL33930First Coast Service Options, Inc.Updated Oct 16, 2026
- Facet Joint Interventions for Pain ManagementLocal determinationTakes effect soonL34892Novitas Solutions, Inc.Updated Oct 16, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Gem", any status and sponsor, newest update first.
- Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05413304 · 5 participants · Start Apr 7, 2023 · Primary completion Oct 21, 2025
Device: Device for Cerebral Fluid Dialysate Collection; Ashion Analytics GEM ExTra · For: Glioma
Sites: Bethesda, Maryland
- Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 DiabetesPivotal-lookingNot yet recruiting
NYU Langone HealthAcademic, hospital or other
NCT07278531 · 120 participants (planned) · Start Feb 2027 · Primary completion Aug 31, 2028
Device: Continuous Glucose Monitoring (CGM) · For: Type 2 Diabetes
Sites: New York, New York
- Focused Ultrasound and Gemcitabine in Breast CancerActive, not recruiting
Patrick Dillon, MDAcademic, hospital or other
NCT04796220 · 32 participants (planned) · Start Jan 27, 2022 · Primary completion Sep 2029
Device: Focused Ultrasound · For: Breast Cancer; Breast Neoplasms
Sites: Charlottesville, Virginia
12 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Gem", and for the whole product code for context.
This brand
877 reports: 785 malfunction, 78 injury, 12 death
Whole product code BZG
21 reports: 16 malfunction, 5 injury, 0 death
Newest reports for this brand
- GEM Microvascular Anastomotic COUPLERMalfunction
1416980-2026-03096 · Received Oct 9, 2026 · Event dated Sep 9, 2026
Device type: Device, Anastomotic, Microvascular (MVR)
Device problem as coded: Misconnection
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- GEM Premier 5000Death
Instrumentation Laboratory Co.
1217183-2026-00030 · Received Sep 25, 2026 · Event dated Apr 28, 2026
Device type: Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph (CHL)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Insufficient Information
- GEM Premier 5000Death
Instrumentation Laboratory Co.
1217183-2026-00031 · Received Sep 25, 2026 · Event dated Apr 28, 2026
Device type: Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph (CHL)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Gem"[tiab]. The summary above synthesizes these.
- Copper-Catalyzed Protoarylation of gem-Difluoroallenes.
Li W, Wang C, Xiao M, et al. · Org Lett · 2024
- Targeting GEM Reprograms Macrophages and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma.
Wu L, Ren C, Zhang Y, et al. · Cancer Res · 2026
- Dichloromethyl(diaryl) Sulfonium Salts as gem-Dichlorocyclopropanation Reagents.
Moore BJ, Willcox D · Org Lett · 2025
- gem-Difluoroallene (DFA): an emerging versatile synthetic precursor to enable diverse fluorinated molecules.
Sathish K, Jain S, Sihag N, et al. · Org Biomol Chem · 2024Review
- Switchable Divergent Electrochemical Hydrodehalogenation of gem-Dihalocyclopropanes.
Pan J, Qu H, Li Y, et al. · J Org Chem · 2024
- TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W, Hu X, He X, et al. · Drug Resist Updat · 2024Research Support, Non-U.S. Gov't
- Stereoselective Desymmetrization of gem-Diborylalkanes by "Trifluorination".
Kumar N, Reddy RR, Masarwa A · Chemistry · 2019
- gem-Difluorination of carbon-carbon triple bonds using Brønsted acid/Bu4NBF4 or electrogenerated acid.
Yamaguchi M, Shimao H, Hamasaki K, et al. · Beilstein J Org Chem · 2024
- DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization.
Deng Z, Zhou F, Li M, et al. · Theranostics · 2025
- A Stereodivergent Approach to the Synthesis of gem-Diborylcyclopropanes.
Hanania N, Nassir M, Eghbarieh N, et al. · Chemistry · 2022
- gem-Diborylalkanes: recent advances in their preparation, transformation and application.
Nallagonda R, Padala K, Masarwa A · Org Biomol Chem · 2018Review
- CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains.
Chancellor A, Tocheva AS, Cave-Ayland C, et al. · Proc Natl Acad Sci U S A · 2017Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code BZG.
- Vitalograph Model 6000 AlphaVitalograph Ireland, Ltd. · 510(k) 2022
- Air Next (NVD-02)Nuvoair AB · 510(k) 2024
- ComPAS2Morgan Scientific, Inc. · 510(k) 2022
- GoSpiroMonitored Therapeutics, Inc. · 510(k) 2020
- Asthma Monitor AM3Eresearch Technology · 510(k) 2019
- SpirotelMir Medical Intl. Research Srl · 510(k) 2013
- MinispirMir Medical Intl. Research Srl · 510(k) 2012
- Chartis ConsolePulmonx, Inc. · 510(k) 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.